Hemangiol in infantile haemangioma: A paediatric post-marketing surveillance drug study.

Floriane SocchiMichele BigorreMarion NormandinGuillaume CaptierDidier BessisMichel MondainCatherine BlanchetMohamed AkkariPascal AmedroArthur Gavotto

Published in: British journal of clinical pharmacology (2020)

This post-marketing surveillance drug study supports the good tolerance of Hemangiol in children with IH. A rapid initiation protocol is of interest when treatment is urgent. The pretherapeutic paediatric cardiology consultation should not be systematic but only indicated for specific patients. CLINICALTRIALS.GOV: NCT04105517.

Keyphrases

public health
end stage renal disease
emergency department
intensive care unit
ejection fraction
young adults
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
cardiac surgery
acute kidney injury